Adequate pre-operative investigations
| QI 6 - Proportion of patients with a pre-operative work-up according to the ESGO/ESTRO/ESP guidelines | |
| Type | Outcome indicator |
| Description | The pre-operative mandatory work-up, based on the ESGO/ESTRO/ESP guidelines, includes: family history; general assessment and inventory of co-morbidities; geriatric assessment, if appropriate; clinical examination, including pelvic examination; expert vaginal or transrectal ultrasound or pelvic MRI. Depending on clinical and pathologic risk, additional imaging modalities (thoracic, abdominal, and pelvic CT scan, MRI, positron emission tomography scan, or ultrasound) should be considered to assess ovarian nodal, peritoneal, and other sites of metastatic disease |
| Specifications |
Numerator: number of patients who have undergone pre-operative work-up according to the ESGO/ESTRO/ESP guidelines (as defined above) Denominator: all patients who have undergone surgery |
| Target | 90% |
| QI 7 - Proportion of presumed FIGO stage I–II upstaged to IVB disease | |
| Type | Outcome indicator |
| Description | Presence of peritoneal carcinomatosis and distant metastases in patients who have been considered early-stage disease (stage I–II) pre-operatively |
| Specifications |
Numerator: number of patients with post-operative stage IVB including peritoneal carcinomatosis Denominator: all patients with presumed stage I–II disease undergoing surgery |
| Target | <5% |